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The ﬁbroblast growth factor receptor substrate (FRS)-2 protein family comprises FRS2a, a well-
known central mediator for ﬁbroblast growth factor signaling, and FRS2b, whose endogenous
expression pattern and function are not yet deﬁned. Immunohistochemical analysis revealed that
expression of FRS2bwas restricted to neural tissues and it colocalized with Tuj1, a neuronal marker.
There are two distinct patterns of FRS2b expression in neural cells: punctate and cup/ring-shaped;
moreover, some particles colocalized with lysosomes. Stimulation with brain-derived neurotrophic
factor (BDNF) enhanced FRS2b phosphorylation and the cup/ring-shaped pattern. These results sug-
gest a probable role of FRS2b in the intracellular degradation systems of neural cells, which involves
lysosomes.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Signal transduction pathways through receptor tyrosine kinases
(RTKs) have pivotal roles in a number of aspects of physiological
and pathological biology, including embryogenesis and tumorigen-
esis [1]. Proteins lacking catalytic activity, the so-called scaffolding
adaptor proteins, relay many key events of signal transduction
from upstream components, such as receptors, to downstream ele-
ments [1–3]. The ﬁbroblast growth factor receptor substrate (FRS)-
2 family proteins are membrane-linked docking proteins belonging
to a subgroup of the scaffolding adaptor proteins [4–6].
In mammals, the FRS2 protein family comprises two members-
FRS2a/SNT-1 and FRS2b/FRS3/SNT-2. Both proteins contain N-ter-
minal myristylation sites for localization to membranes, including
the plasma membrane, and a phosphotyrosine binding (PTB) do-
main for binding to RTKs, such as the ﬁbroblast growth factor
(FGF) receptor and neurotrophin receptor [7–9]. Following activa-
tion of these RTKs, FRS2 proteins are phosphorylated on tyrosinechemical Societies. Published by E
ptor substrate-2; FGF, ﬁbro-
DNF, brain-derived neurotro-
h).residues and bind to an SH2 domain-containing adaptor, Grb2,
and a tyrosine phosphatase, Shp2 [10,11]. Subsequently, Shp2 acti-
vates a Ras/ERK pathway and Grb2 activates the Ras/ERK, phospha-
tidyl inositol (PI)-3 kinase, and ubiquitination/degradation
pathways by binding via its SH3 domain to Son of sevenless
(SOS), Grb2-associated binder-1 (Gab1), and c-cbl protooncogene
product (Cbl), respectively. FRS2a is a central mediator in FGF sig-
naling. In particular, genetically engineered FRS2a mutant mice
exhibit a variety of developmental defects because of problems
with FGF signaling in vivo [12–15].
In contrast to FRS2a, the functions of FRS2b have not been well
elucidated. FRS2b compensates for the loss of FRS2a by activating
ERK in Frs2a/mouse embryonic ﬁbroblasts (MEFs) in response to
FGF [8]. FRS2 proteins bind to FGF receptor with or without recep-
tor activation [7,16]. In contrast, the binding between FRS2 pro-
teins and Trks are receptor activation dependent [9,17,18]. The
signaling pathways downstream of FRS2 proteins via activation
of Trks are similar to that of FGF signaling, Grb2, Shp2 and SOS
are recruited and ERK is activated [7,8,19,20]. The potential of
activated FRS2b to promote the neuritogenesis was demonstrated
by overexpression studies [9,21]. Recent in vitro experiments
showed that FRS2b inhibits signaling by the epidermal growth
factor (EGF) RTK. The evidence for this came from the ﬁnding that
FRS2b expression inhibits EGF-induced cell proliferation andlsevier B.V. All rights reserved.
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receptors constitutively; however, EGF RTK does not phosphory-
late the tyrosine residues of FRS2b. Instead, FRS2b appears to inhi-
bit the tyrosine kinase activity of the EGF receptor. In contrast, in
cells where EGF receptors are overexpressed, the tyrosine residues
of FRS2a are phosphorylated by EGF RTK [24]. Therefore, FRS2b is a
unique scaffolding adaptor that serves as a negative as well as a po-
sitive regulator for RTK signaling, depending on the receptor
species.
It is obvious that FRS2 proteins are key molecules involved in a
variety of biological events, including embryogenesis; therefore,
the precise analysis of normal expression levels of these proteins
is necessary. We have previously shown by in situ hybridization
that the transcripts of Frs2a and Frs2b are expressed in several tis-
sues in mouse embryos [8]. However, information is scarce about
endogenous FRS2b protein expression.
In this study, we aimed to examine the expression patterns of
FRS2b protein in tissues as well as its intracellular localizations
by using a newly generated anti-FRS2b antibody, and have eluci-
dated the probable endogenous roles relating to intracellular vesi-
cles in neural cells.
2. Materials and methods
2.1. Monoclonal anti-FRS2b antibody production by baculovirus
system and polyclonal anti-FRS2a antibodies
Mouse monoclonal antibody against human FRS2b was raised
by immunizing mice with recombinant baculovirus particles dis-
playing a C-terminal region (antigen-1; 368–421 a.a., antigen-2;
446–492 a.a.) of FRS2b as fusion proteins to the viral surface glyco-
protein gp64, as previously described [25,26]. Positive hybridomas
were screened by enzyme-linked immunosorbant assay (ELISA)
and Western blotting (WB). After screening candidates, one of
the obtained antigen-1 clones, designated clone Y7624, was se-
lected for this study. To ensure that Y7624 does not cross react
with FRS2a, we also generated anti-FRS2a antibodies. The peptide
corresponding to human FRS2a (401–493 a.a.) was synthesized as
glutathione S-transferase (GST)-fusion protein by using the pGEX
expression vector (6p-1, GE Healthcare). After proteolytic cleavage
and removal of GST, puriﬁed FRS2a peptides were mixed with Fre-
und’s Complete Adjuvant (FCA) or Freund’s Incomplete Adjuvant
(FEA) and rabbits were immunized. The serum of immunized rab-
bits was subjected to afﬁnity puriﬁcation and one of the obtained
antibodies was designated anti-FRS2a (a35).
2.2. Cell culture and transfection
HEK293T cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) containing 10% fetal bovine serum at 37 C in
5% CO2. Subsequently, the cells were lysed and subjected to immu-
noprecipitation followed by WB analysis. HEK293T cells were
transfected with 2 lg of plasmid of mammalian expression vector
pcDNA carrying cDNA encoding FRS2a or FRS2b [8] by using Lipo-
fectAMINETM plus reagents (Invitrogen), according to the manufac-
turer’s instructions.
2.3. Immunoprecipitation and immunoblot analysis
Immunoprecipitation and Western blot analysis were per-
formed as previously described [8,10]. In brief, proteins were sep-
arated by 8% sodium dodecyl sulfate (SDS)–PAGE and were
electrophoretically transferred onto a polyvinylidene diﬂuoride
membrane. The membrane was blocked with 5% low-fat milk in
Tris–buffered saline with 0.1% Tween 20 (TBS-T) and then incu-bated with primary antibodies for analyzing all protein except
phosphorylated proteins. For phosphorylated proteins, membranes
were blocked with 3% BSA in TBS-T. The primary antibodies used
are as follows: anti-FRS2a (a35), anti-FRS2b (Y7624), anti-M2 Flag
(SIGMA), anti-actin (Chemicon), anti-phospho tyrosine (4G10, MIL-
LIPORE), anti-myc, anti-pTrk, and anti-Trk (pan) (Cell Signaling
Technology). All the antibodies were labeled with horseradish per-
oxidase-conjugated secondary antibodies, and were analyzed
using Immobilon Western (Millipore).
2.4. Primary culture of embryonic cortical neurons
Cortical neurons were isolated from embryonic day (E) 14.5 ICR
mice using a nerve cell culture system (Sumilon) in a standard pro-
cedure with minor modiﬁcations. Harvested cells were plated onto
35-mm dishes and 4-well chamber slides (5  105 cells/ml) pre-
coated with poly-L-Lysine, and cultured for 4 days in Neurobasal
medium supplemented with B27 supplement (GIBCO). The med-
ium was changed on the 2nd day and these cultured cells were
used on the 4th day for the experiments.
2.5. Histological analysis of FRS2b by in situ hybridization and
immunoﬂuorescence
Adult ICR mouse (4-week-old male) brain and E14.5 ICR mouse
head specimens ﬁxed with 4% paraformaldehyde (PFA) were used
for performing section RNA in situ hybridization (ISH) and immu-
nohistochemistry after routine cryosection processing. The digoxi-
genin (DIG)-coupled uridine triphosphate (UTP) labeled mouse
Frs2b in situ probes were described previously [8] and the ISH
procedure was conducted as previously mentioned [8]. After
hybridization, the sections were counterstained with Nuclear Fast
Red (Vector Lab).
Immunoﬂuorescence was performed with a directly labeled pri-
mary antibody using Zenon Labeling Kits (Invitrogen). For immu-
nohistochemistry of tissue cryosections, permeabilization was
performed with 0.1% Triton X-100 in phosphate-buffered saline
(PBS) for 3 min. During immunocytochemical analysis, we noticed
that use of the Triton X-100 solution for permeabilization attenu-
ated the FRS2b punctate pattern and rendered it almost indiscern-
ible (data not shown). Since saponin has been successfully used for
staining of intracellular vesicle membranes [19], we permeabilized
the cells with 0.2% saponin in PBS instead of Triton X-100. The pri-
mary antibodies used for immunoﬂuorescence were as follows:
anti-FRS2b (Y7624), anti-tubulin beta III isoform (TuJ1, Covance),
anti-GFAP (Dako), anti-O4 (Millipore), and anti-EEA1 (BD Biosci-
ences). LysoTracker (Invitrogen) was used according to the instruc-
tions provided. For negative control slides of serial sections, we
used a mixture of mouse IgGs and IgM (Dako) instead of the pri-
mary antibody. The specimens were counterstained with DAPI,
routinely observed, and photographed with AxioVision (Zeiss).
For confocal imaging and 3D-constructions, images were captured
with a CSF-Frontier system with CSU-X1 confocal scanner unit
(Yokogawa) and Andor iXon EM/EMCCD camera (DU897), and
micrographs were analyzed and 3D constructions were made by
using the Andor iQ imaging software.
3. Results and discussion
3.1. Establishment of monoclonal anti-FRS2b antibody
For the evaluation of the newly generated antibodies, HEK293T
cells were transiently transfected with an expression vector carry-
ing the cDNA of FLAG-tagged FRS2a or FLAG-tagged FRS2b. The cell
lysates were immunoprecipitated with anti-FLAG antibody,
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FRS2a antibodies (a35). FRS2a and FRS2b expression were con-
ﬁrmed in each whole cell lysate and immunoprecipitates with
anti-FLAG antibody (Fig. 1A, middle panel) by WB. Anti-FRS2b
(Y7624) antibody bound to only FRS2b without cross reacting with
FRS2a, while anti-FRS2a antibodies (a35) bound to only FRS2a
without cross reacting with FRS2b (Fig. 1A, upper panel vs. lower
panel). No extraneous bands were observed with whole cell ly-
sates. The speciﬁcity of these antibodies was also conﬁrmed in
an shRNA knockdown study in stable transfectants of myc-tagged
FRS2b in NIH3T3 cells (Supplementary Fig. 1A) where the expres-
sion of FRS2b was suppressed. We also examined clone Y7624
for immunocytochemistry with exogenous expression of HA-
tagged FRS2b, and conﬁrmed the colocalization of HA-immunoﬂu-
orescence with Y7624-immunoﬂuorescence in HA-FRS2b transfec-
ted cells (data not shown).
3.2. Expression of FRS2b predominantly in brain in adult mice
Next, we examined the expression of FRS2a and FRS2b in adult
mouse tissues. First, real time quantitative reverse transcriptaseFig. 1. Establishment of anti-FRS2b (Y7624) antibody. Mouse monoclonal antibody
generated from baculovirus-based gp64 fusion FRS2b was subjected to afﬁnity
puriﬁcation and then used for immunoprecipitation (IP) and Western blot (WB)
analysis. HEK293T cells transiently transfected with FLAG-tagged FRS2a (FRS2a-
FLAG), FLAG-tagged FRS2b (FRS2b-FLAG), or empty vector (293T) were immuno-
precipitated with anti-FLAG antibody (IP-Flag). Immunoprecipitates and whole cell
lysates (Whole) were analyzed by immunoblotting with anti-FRS2b antibody
(upper panel of A). Thereafter, the membrane was reprobed with an anti-Flag
antibody and further reprobed with anti-FRS2a antibody and anti-actin antibody
(lower panels of A).polymerase chain reaction (qRT-PCR) revealed that Frs2a mRNA
was expressed in all the adult mouse tissues tested, including
brain, lung, stomach, small intestine, colon, liver, and kidney, while
Frs2bmRNA expression was highly restricted to brain (Supplemen-
tary Fig. 2A and B). Next, we prepared tissue lysates derived from a
4-week-old ICR mouse. As shown in Fig. 2A, immunoreactive single
bands of FRS2b were clearly detected with cell lysate from
HEK293T cells exogenously expressing FRS2b as positive control
(FRS2b), in the lanes with whole mouse brain lysate (Brain), and
in the lanes containing immunoprecipitate of mouse brain lysate
with anti-FRS2b antibody (IP-Brain). Other tissues were negative.
These results are consistent with those obtained in the qRT-PCR
analysis. Thereafter, the membrane was stripped and reprobed
with anti-FRS2a antibody; expression of FRS2a was seen at vary-
ing levels in all the tissues tested (Supplementary Fig. 2C and D).
This further demonstrates that the Y7624 antibody is speciﬁc only
for FRS2b, and proves that it can detect the endogenous levels of
FRS2b without cross reacting with FRS2a protein.
Next, we examined the expression of Frs2b mRNA by in situ
hybridization. As shown in Fig. 2B and C, Frs2b mRNA expression
was strongly detected in the cerebral cortex (Cor), hippocampus
(HPC), and cerebellum in the adult mouse brain. This expression
pattern was conﬁrmed by immunohistochemistry with anti-FRS2b
antibody (representative micrographs in Fig. 2G–I). Immunoﬂuo-
rescence of FRS2b exhibited a punctate pattern when observed
with a higher magniﬁcation (Fig. 2J–L). These FRS2b puncta were
observed in pyramidal cells of Cor (Fig. 2G and J, arrows in G), CA
regions, dentate gyrus (DG) of HPC (representative micrograph
from CA2 region in Fig. 2H and K), and in the Purkinje (Pu) and
granule cells (CGC) of the cerebellum (Fig. 2I and L). Puncta were
not observed in the negative control slides of adjacent serial sec-
tions (Fig. 2D–F).
3.3. Restricted expression of FRS2b protein in neural tissues of mouse
embryos
We next performed histological examinations with embryonic
tissues. We had previously reported distinct Frs2b mRNA expres-
sion in mouse embryo by in situ hybridization, which was re-
stricted predominantly in neuroepithelium [8]. In brief,
prominent Frs2b mRNA expression in the central nervous system
was restricted to mesencephalon, diencephalon (hypothalamus),
and cranial ganglia, such as the trigeminal (V) ganglia (Figs. 1
and 2 of [8]). In the peripheral nervous system, dorsal root ganglia
(DRG) exhibited a plentiful expression of Frs2b mRNA (Fig. 1 of
[8]). Considering these tissues as positive controls, we examined
the FRS2b protein expression in E14.5 mouse embryos. As shown
in Fig. 3D (telencephalon), G (mesencephalon), M (diencephalon;
hypothalamus), P (trigeminal (V) ganglia), and S (DRG), prominent
FRS2b protein expression was detected in the previously reported
tissues. Faint immunoﬂuorescence was observed in the negative
control slides of adjacent serial sections; representative results
for the negative control are shown in Fig. 3A and B. As shown in
Fig. 3C and D (asterisk indicates ventricular side), in situ hybridiza-
tion and immunohistochemical analysis revealed that both FRS2b
mRNA and protein were abundantly expressed in cortical plate
(CP)/intermediate zone (IMZ)-proximal rather than in the
ventricular zone (VZ)/subventricular zone (SVZ). Neural stem cells
self-renew and undergo asymmetrical cell division to produce dif-
ferentiating daughter cells in VZ at this stage, and the differentiat-
ing cells migrate toward the CP. Through this transition, cells
differentiating to a neuronal linage become positive for the neuro-
nal marker Tuj1 as they reach the CP/IMZ. Most of the FRS2b posi-
tive cells were also positive for Tuj1 (Fig. 3D–F0, G–I0, J–L0, M–O0, P–
R0 and S–U0). We found by in situ hybridization that Frs2b mRNA
expression was also detected in developing retina (Supplementary
Fig. 2. Expression of FRS2b protein in adult mouse tissues. In Western blotting endogenous FRS2b in adult mouse brain was detected with the newly established anti-FRS2b
antibody as a single band (A). See Supplementary Fig. 2 for comparative analysis of mRNA and protein expressions of FRS2b vs. FRS2a in adult mouse tissues. Representative
results of in situ hybridization analysis in adult mouse brain (B and C). Frs2b mRNA (blue staining) was strongly detected in cerebral cortex (Cor) (B) and CA regions and
dentate gyrus (DG) of hippocampus (HPC) (B) and in cerebellum (C). Immunohistochemical analysis of FRS2b protein expression (D–L). Directly labeled anti-FRS2b antibody
detected FRS2b protein with essentially the same distribution as seen for the mRNA in the in situ hybridization analysis; representative micrographs of Cor (G), CA2 region of
HPC (H), and the cerebellum (I) are shown. No immunoﬂuorescence was observed in the respective negative control slides with adjacent sections (D–F). Under higher
magniﬁcation, punctate labeling of FRS2bwas observed in these specimens (J–L, corresponding to the images of G–I, respectively). Pu, Purkinje cells; CGC, granule cells. Scale
bars = 100 lm (B–I). Scale bars = 10 lm (J–L).
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FRS2b-positive cells were also detected in developing retina (Sup-
plementary Fig. 3B–D, H–J0, representative negative controls are
shown in Supplementary Fig. 3E–G), and the medulla of adrenal
gland (Supplementary Fig. 3K–M0). The punctate pattern of expres-
sion seen in the adult was also found in embryonic neural tissues,
especially in differentiated Tuj1-positive neural cells (Fig. 3F0, I0, L0,
O0, R0, U0, Supplementary Fig. 3J0 and M0). At this stage, the cells in
VZ/SVZ in telencephalon, including neural stem and progenitor
cells (NSPCs), were negative for both TuJ1 and FRS2b (Fig. 3D–F).
We demonstrated previously that FRS2a plays a critical role in
the proliferation of NSPCs in response to FGF in vitro and in the
development of intermediate progenitor cells that are derived from
radial glial neural stem cells and one-step committed to the neuro-
nal lineage in the VZ/SVZ [15]. Although FRS2b can substitute the
FGF-induced ERK stimulation in Frs2a/ MEFs in in vitro studies
[8], our ﬁndings of poor colocalization of FRS2a and FRS2b in VZ/
SVZ indicates that here FRS2b is not expressed to substitute for
FRS2a with respect to FGF signaling. It has also been reported that
EGF receptors are expressed in cortical NSPCs and generate diverse
progenitor cells in the central nervous system (CNS) [27]. On the
basis of the EGF receptor expression observed in VZ/SVZ and thenegative effect of FRS2b on EGF signaling [23], a lack of FRS2b
expression in the VZ/SVZmay be related to a need for EGF signaling
there. Thus, we hypothesize that different expression patterns of
FRS2b and FRS2a are attributed to their distinct functional
properties.
3.4. Expression of FRS2b protein in primary culture of embryonic
neural cells
Further, we analyzed the consistent punctuate manner of FRS2b
by using puriﬁed primary culture of E14.5 cortical neurons. As
shown in Fig. 4, the punctate pattern of FRS2b expression, as re-
vealed by immunoﬂuorescence, clearly persisted in cultured cells
after 4 days in vitro; the majority of FRS2b-positive cells were
Tuj1-positive neuronal cells (Fig. 4A–D), while only a few Tuj1-
negative cells were also found to express FRS2b (Fig. 4N, arrows).
Therefore, we used two other markers, GFAP and O4, for detecting
astrocytes and oligodendrocytes, respectively. As shown in Fig. 4E–
L (arrowheads), O, and P, both GFAP- and O4-immunoreactive cells
expressed FRS2b. These puncta of FRS2b immunoﬂuorescence were
observed mainly in the soma (Fig. 4N–P, closed arrowheads) and
occasionally in neurites (Fig. 4N–P, open arrowheads).
Fig. 3. Expression of FRS2b protein in embryonic mouse tissues. Representative Frs2b in situ hybridization analysis in the E14.5 telencephalon showed abundant Frs2bmRNA
expression (blue staining) in the region distant from the ventricular side () (C); prominent FRS2b protein expression was shown in the same manner, i.e., FRS2b is found in
the Tui1-positive region (D–F). No immunoﬂuorescence was observed in the respective negative control slides of serial sections; representative results of negative control are
shown in (A and B). FRS2b expression in Tuj1-positive regions was conﬁrmed in mesencephalon (G–I), cerebella primordium (J–L), hypothalamus (M–O), trigeminal (v)
ganglia (P–R), and dorsal root ganglia (S–U). Cropped and magniﬁed micrographs demonstrate that the immunoﬂuorescence of FRS2b again appears in a punctate manner (F0 ,
I0 , L0 , O0 , R0 , and U0). , ventricular side (A–L); #, optic recess (M–O); CP, cortical plate; IMZ, intermediate zone; SVZ, subventricular zone; VZ, ventricular zone. Scale bar in
(C) = 100 lm. Other scale bars = 10 lm. Representative micrographs of other Tuj1-positive tissues, developing retina and adrenal, are shown in Supplementary Fig. 3.
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vesicles
Microscopic examination revealed not only a punctate pattern
of FRS2b expression but also cup/ring-shaped structures. This
suggested a relationship to intracellular vesicles [28,29]. There-
fore we used vesicle markers to determine whether FRS2b-
immunoﬂuorescence colocalizes intracellular vesicles. Represen-
tative micrographs are shown in Fig. 5A–D. Some puncta of
FRS2b immunoﬂuorescence showed colocalization with EEA1, a
marker for early endosomes (Fig. 5A and C, arrowheads), and
LysoTracker-positive lysosomes (Fig. 5B and D, arrowheads). We
quantiﬁed the colocalized vesicles by using confocal microscopy
and we found that FRS2b immunoﬂuorescence was colocalized
with lysosomes 4.7-fold more often than with endosomes
(Fig. 5E). The cup/ring-shaped pattern of FRS2b immunoﬂuores-
cence was seen only in conjunction with lysosomes (Fig. 5B0
and cropped micrographs in 5D, arrows), and not with endo-
somes (Fig. 5C and cropped micrographs). Three-dimensional
construction imaging analysis provided evidence that cup/ring-shaped FRS2b immunoﬂuorescence surrounds the lysosomes
(Supplementary Animation 1).
To examine whether the pattern of FRS2b expression is inﬂu-
enced by phosphorylation, primary cultured cells were stimulated
with BDNF (100 ng/ml, 15 min). The FRS2b phosphorylation was
conﬁrmed by Western blotting, with FRS2b appearing as a doublet
band (Fig. 6A, upper panel set); it was also conﬁrmed by probing
the blot with anti-phosphotyrosine antibody (Fig. 6A, lower panel
set). The frequency of association with cup/ring-shaped structures
was increased under FRS2b phosphorylation (representative
micrographs in Fig. 6B and C). BDNF stimulation induced a ca.
3.4-fold increase in the proportion of cup/ring-shaped structures
associated with FRS2b (Fig. 6D) and the number of cup/ring-shaped
structure per cell was signiﬁcantly increased in the BDNF treated
cells (4.90 ± 1.34) compared to the untreated cells (1.57 ± 0.57).
(P = 0.041, Student’s paired t-test, the results are presented as
means ± S.E.).
In this study we have used a monoclonal antibody to investi-
gate the intracellular localization of endogenous FRS2b in neural
cells. From the dynamics of the FRS2b immunoﬂuorescence
Fig. 4. FRS2b expression in primary cultured embryonic neural cells. Double immunostaining of FRS2b was carried out with the following neural cell markers: Tuj1 as
neuronal marker, GFAP as astrocyte marker, and O4 as oligodendrocyte marker. Embryonic cortical neurons were puriﬁed from E14.5 mouse and cultured for 4 days. Most of
the harvested cells were Tuj1-positive neuronal cells and exhibited an abundant FRS2b expression (A–D), while some Tuj1-negative cells were found to express FRS2b (N,
arrows). Further analysis revealed that FRS2b is also expressed in GFAP-positive cells (E–H and O, arrowheads) and O4-positive cells (I–L and P, arrowheads). Slight
immunoﬂuorescence of background was observed in negative control (M). The puncta of FRS2b immunoﬂuorescence were mainly in soma (N–P, closed arrowheads) and
occasionally in neurites (N–P, open arrowheads). Scale bars = 10 lm.
Fig. 5. FRS2b and its colocalization with intracellular vesicles by marker staining. EEA1 for early endosome (red in A and C) and LysoTracker for lysosomes (red in B and D)
were analyzed together with FRS2b immunoﬂuorescence (green in A–D) in primary cultured embryonic neural cells. Arrowheads indicate colocalization of FRS2b and each
marker. Confocal microscopy and 3D-construction imaging revealed that cup/ring-shaped FRS2b immunoﬂuorescence surrounds lysosomes (arrows in B0 and lower panels of
D) (see Supplementary Animation 1). The frequency of FRS2b colocalization with lysosomes was higher than that seen with early endosomes (E). Graphs depict the
quantiﬁcation of FRS2b colocalization with EEA1 (three independent experiments; total 184 vesicles/15 cells), or with LysoTracker (three independent experiments; total 187
vesicles/16 cells). Scale bar = 10 lm.
812 Y. Minegishi et al. / FEBS Letters 583 (2009) 807–814associated with intracellular vesicles, we conclude that FRS2b is
not only a signal transducer, but also appears to have a probablerole for intracellular transport and function, most likely intracel-
lular degradation by lysosomes.
Fig. 6. Effect of FRS2b phosphorylation. Primary cultured embryonic neural cells
were stimulated with BDNF (100 ng/ml, 15 min). FRS2b phosphorylation was
shown by IP with anti-FRS2b antibody (7624Y) followed by Western blotting with
the indicated antibodies. Phosphorylation of FRS2b in doublet bands of FRS2b
(upper panel set in A, arrowheads) and was also shown in immunoprecipitates with
anti-FRS2b antibody followed by blotting with anti-phosphotyrosine antibody
(lower panel set in A, arrowheads). Blots of whole lysates were also probed with
anti-phospho Trk and anti-Trk antibodies (upper panel set in A). Immunoﬂuores-
cence showing FRS2b puncta (white arrowheads) and cup/ring-shaped structures
(white arrows) under without (B) or with (C) BDNF stimulation. Scale bar = 10 lm.
The proportion of cup/ring-shaped FRS2b structures increased under FRS2b
phosphorylation (D). Graphs depict the proportion of FRS2b structures without
stimulation (two independent experiments; total 149 vesicles/11 cells), or with
BDNF stimulation (three independent experiments; total 195 vesicles/14 cells).
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in the internalization of neurotrophins and the receptor complex
are still unclear, but some notions mention that the ligand-induced
RTK phosphorylation is important for its internalization and endo-
cytosis. The internalization of the neurotrophin-Trk receptor com-
plex is critical for many aspects of neural functions, e.g., neural cell
survival and arborization of dendrite to make proper network of
neurons [30,31]. Ligand-induced endocytosis of RTKs such as Trk
and EGF receptor require tyrosine kinase activity of the receptor
[32–34]. One of the mechanisms by which FRS2b negatively regu-
lates the EGF signaling could be that FRS2b brings the RTK complex
and the substrates to lysosomal degradation via intracellular
sorting.
The tyrosine phosphorylation-dependent interaction of FRS2b
with TrkB has been demonstrated in vitro [17]; the activation of
FGF receptor 1 kinase enhances its interaction with FRS2a but
not with FRS2b [35]. These observations support the notion that
FRS2a but not FRS2b contributes to the FGF signal axis as a main
signal transducer. Nevertheless, in order to further understand its
intracellular physiological functions, it is important to ﬁnd well-
suited RTKs that are present upstream of the endogenous FRS2b.
Further investigations by tracing FRS2b as a marker of internalized
signaling molecules associated with intracellular membrane would
yield valuable insights.
The intracellular transport/sorting and degradation/recycling
process of neurotrophins and their receptors are also important
from the clinical aspect. As mentioned earlier, Trks are important
for neuritogenesis in the formation of neural circuits. Lack of Trks
results in impaired neurogenesis and the speciﬁc lack of TrkB sig-
naling in neurons of hippocampus in newborn mice remarkably in-
creased anxiety-like behavior [31]. Dysfunction of intracellular
degradation systems is thought to evoke neurodegenerative dis-eases [36]. Transportation of neurotrophins to their proper desti-
nations is critical for the construction of ﬁne neural networks
that maintain normal brain function [31,37–39]. Further, hyperac-
tivation of TrkB signaling is implicated in brain tumor growth
[40,41]. Therefore, elucidation of the sorting process of the inter-
nalized neurotrophins and its complexes is important in order to
ﬁnd new therapies for the treatment of brain diseases. Further
investigation in the pathophysiology of actual cellular responses
evoked by internalization of extracellular ligands/RTKs and the
proper transportation via intracellular vesicles associated with
FRS2b is necessary.
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